



Clinical performance and cost-effectiveness of a silicone foam dressing with 3DFit Technology in chronic wounds compared with standard of care: An open randomised multi-centre investigation.

A multi-center study¹ in the UK comparing the clinical performance and cost-effectiveness of Biatain® Silicone to the current standard of care – an Aquacel® Extra filler combined with a Mepilex® Border secondary dressing – showed that Biatain Silicone was equally effective,² while being significantly more cost-efficient,³ than the two-dressing regime over a four-week study period.

Baseline (n=102)

77.5% venous leg ulcers
22.5% diabetic foot ulcers

 43.1%
female

 56.9%
male

Mean wound age: 5.4 months
Mean wound depth: 2.5 mm
Mean wound area: 5.8 cm²

Clinical performance comparison



Wound area
reduction⁴

54.3%	Mean difference: 11.3% p-value=0.299 ⁵
43%	
Biatain Silicone	
Standard of Care	



Wound depth
reduction⁴

72%	Mean difference: 11.4% p-value=0.165
60.7%	
Biatain Silicone	
Standard of Care	

Cost comparison



Estimated total costs (mean)

Significant cost reduction of **33%**³
(p-value= 0.033) when using Biatain Silicone

Biatain Silicone – **£14.3**
Standard of Care – **£21.4**



Number of products (mean)

47% product reduction when using
Biatain Silicone
Biatain Silicone – **5.6**
Standard of Care – **10.6**



Discussion

The results show that Biatain Silicone's clinical performance was just as effective as the two-dressing regime.²



Conclusion

This simplified one-dressing treatment regime reduces costs, as it requires fewer products per patient and frees up time and costs associated with dressing changes. This benefits patients, healthcare providers and the environment.³

1. Voegeli D, Landauro MH, Sperup T, Ayoub N, McRobert JW. Clinical performance and cost-effectiveness of a Silicone foam with 3DFit™ technology in chronic wounds compared with standard of care: An open randomised multicentre investigation. *Int Wound J*. 2024; 21(12). Study sponsored by Coloplast. 2. In wounds up to 2cm in depth. 3. Based on UK pricing data. 4. Two study populations were predefined for statistical analysis. The Intention to treat (ITT) population was the full analysis set, including all randomised participants with valid, informed consent, who had been exposed to at least one product. The per protocol population was a subset defined for the purposes of identifying a treatment effect under optimal conditions to validate the findings with the ITT population. The results of the ITT population are detailed above. 5. A p-value of >0.05 means that the difference is not statistically significant.

™™ Third party brands are property of their respective owners.

For illustrative purposes only. This information is not intended to constitute medical or business advice or in any way replace the independent medical judgment of a trained and licensed physician with respect to any patient needs or circumstances and may not be representative of all patient outcomes. Actual amounts, performance, outcomes, and experience may vary. Please see complete product instructions for use, including all product indications, contraindications, precautions, and warnings.

This example is only intended to be used as an example to help demonstrate the potential cost/resource/time of using Biatain® Silicone. Coloplast does not guarantee any particular financial savings through use of its products.